New study tracks side effects of leading lung cancer therapies
NCT ID NCT07215962
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 21 times
Summary
This study observes 300 adults with advanced non-small cell lung cancer whose tumors have very low PD-L1 levels (below 1%). Researchers are tracking side effects and healthcare use from common first-line treatments like nivolumab plus ipilimumab, with or without chemotherapy. The goal is to understand real-world safety, not to test a new cure or treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Florida Cancer Specialists & Research Institute
Fleming Island, Florida, 32003, United States
Conditions
Explore the condition pages connected to this study.